Anavex Life Sciences Corp (AVXL)

[XenaLives]

These are the big boys in CNS and with successful trials I think Anavex will place in the first year or two. The indications for 2-73 will be that broad.

 
 #	Company	2018 ($m)	2017 ($m)	Growth ($m)	Growth (%) 
 1	Biogen Inc	       $10,066	$9,657	409	4.24% 
 2	Pfizer Inc	        $8,611	$8,569	42	0.49% 
 3	Novartis AG	        $4,773	$4,701	72	1.53% 
 4	Allergan Plc	        $4,734	$4,569	165	3.61% 
 5	Johnson & J.	        $4,230	$4,332	-102	-2.35% 
 6	Sanofi  	        $3,676	$3,339	337	10.09% 
 7	Teva Pharma        	$2,961	$3,972	-1011	-25.45% 
 8	Shire Plc	        $2,914	$2,666	248	9.30% 
 9	Otsuka Hldg Co Ltd	$2,790	$2,429	361	14.86% 
 10	UCB SA	$2,633	        $2,467	166	6.73% 
 11	H. Lundbeck AS       	$2,057	$1,963	94	4.79% 
 12	GlaxoSmithKline         $1,793	$1,857	-64	-3.45% 
 13	Merck KGaA	        $1,746	$1,858	-112	-6.03% 
 14	MallInckrodt Plc	$1,746	$1,663	83	4.99% 
 15	Sumitomo Dainippon Ltd	$1,672	$2,024	-352	-17.39% 
 16	Merck & Co Inc	        $1,561	$1,396	165	11.82% 
 17	Eli Lilly and Co	$1,465	$1,953	-488	-24.99% 
 18	Takeda Pharmaceutical   $1,343	$1,106	237	21.43% 
 19	Jazz Pharmaceuticals 	$1,341	$1,238	103	8.32% 
 20	Eisai Co Ltd	        $1,069	$1,039	30	2.89% 
 

http://www.pmlive.com/top_pharma_list/cns_revenues